Interleukin-8, produced by intratumoral and circulating myeloid cells, correlates with an immunosuppressive myeloid-enriched tumor microenvironment and adverse cancer prognosis.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade
Journal of Experimental & Clinical Cancer Research Open Access 16 March 2024
-
Single-cell transcriptome profiling of the stepwise progression of head and neck cancer
Nature Communications Open Access 24 February 2023
-
The tumor and plasma cytokine profiles of renal cell carcinoma patients
Scientific Reports Open Access 04 August 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ha, H., Debnath, B. & Neamati, N. Theranostics 7, 1543–1588 (2017).
Alfaro, C. et al. Cancer Treat. Rev. 60, 24–31 (2017).
Sanmamed, M. F. et al. Ann. Oncol. 28, 1988–1995 (2017).
Schalper, K.A. et al. Nat. Med. https://doi.org/10.1038/s41591-020-0856-x (2020).
Yuen, K.C. et al. Nat. Med. https://doi.org/10.1038/s41591-020-0860-1 (2020).
McDermott, D. F. et al. Nat. Med. 24, 749–757 (2018).
Mariathasan, S. et al. Nature 554, 544–548 (2018).
DeNardo, D. G. & Ruffell, B. Nat. Rev. Immunol. 19, 369–382 (2019).
Freidlin, B. & Korn, E. L. Nat. Rev. Clin. Oncol. 11, 81–90 (2014).
Hayes, D. F. Mol. Oncol. 9, 960–966 (2015).
Bilusic, M. et al. J. Immunother. Cancer 7, 1–8 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Z.B. receives research support from Bristol-Myers Squibb and Genentech/imCore. T.C. receives research support from and consults for Roche, Bristol-Myers Squibb, Exelixis, Merck, Pfizer, EMD Serono and AstraZeneca.
Rights and permissions
About this article
Cite this article
Bakouny, Z., Choueiri, T.K. IL-8 and cancer prognosis on immunotherapy. Nat Med 26, 650–651 (2020). https://doi.org/10.1038/s41591-020-0873-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-020-0873-9
This article is cited by
-
Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade
Journal of Experimental & Clinical Cancer Research (2024)
-
Single-cell transcriptome profiling of the stepwise progression of head and neck cancer
Nature Communications (2023)
-
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer
British Journal of Cancer (2023)
-
Enabling Chemo-Immunotherapy with HIFU in Canine Cancer Patients
Annals of Biomedical Engineering (2023)
-
The tumor and plasma cytokine profiles of renal cell carcinoma patients
Scientific Reports (2022)